Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine
Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial

Detailed analyses reinforce the safety profile of resmetirom

Resmetirom has the potential to become the first and only medicine approved for NASH; PDUFA date is March 14, 2024

Today, February 8, 2024, Madrigal Pharmaceuticals (This content is for paid subscribers.

Please click here to subscribe or here to log in.